和黄医药(00013.HK)“沃瑞沙”治疗非小细胞肺癌新适应症上市申请获批

阿斯达克财经

2025/01/14

和黄医药(00013.HK) 宣布，与阿斯利康(AZN.US) 共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准，意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。和黄医药研发负责人兼...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503599047"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503599047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503599047?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg","is_english":false,"pubTime":"2025-01-14 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503599047","market":"other","top_or_hot":-1,"title":"和黄医药(00013.HK)“沃瑞沙”治疗非小细胞肺癌新适应症上市申请获批","media":"阿斯达克财经","content":"<div>\n<p>和黄医药(00013.HK) 宣布，与阿斯利康(AZN.US)  共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准，意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。和黄医药研发负责人兼...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410201/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013.HK)“沃瑞沙”治疗非小细胞肺癌新适应症上市申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013.HK)“沃瑞沙”治疗非小细胞肺癌新适应症上市申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-14 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410201/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>和黄医药(00013.HK) 宣布，与阿斯利康(AZN.US)  共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准，意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。和黄医药研发负责人兼...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410201/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410201/latest-news/AAFN","article_id":"2503599047","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410201/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2503599047","pubTimestamp":1736827260,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"和黄医药宣布，与阿斯利康共同开发的口服间质-上皮转化因子酪氨酸激酶抑制剂“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。阿斯利康中国肿瘤业务总经理关冬梅指出，通过与和黄医药合作，可推动沃瑞沙用于解决对EGFR-TKI1的耐药性，为治疗MET突变和扩增癌症开启新的可能性。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00013":"和黄医药","BK1587":"次新股","BK1588":"回港中概股","BK1191":"制药"},"translate_title":"Chi-Med's (00013. HK) \"Vorisa\" marketing application for new indications for the treatment of non-small cell lung cancer was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"和黄医药(00013.HK) 宣布，与阿斯利康(AZN.US)  共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准，意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。和黄医药研发负责人兼首席医学官石明表示，未来将进一步推动研究并扩展沃瑞沙的可及性，将继续探索沃瑞沙在其他MET驱动疾病中的应用。阿斯利康中国肿瘤业务总经理关冬梅指出，通过与和黄医药合作，可推动沃瑞沙用于解决对EGFR-TKI1的耐药性，为治疗MET突变和扩增癌症开启新的可能性。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}